Displaying drugs 14326 - 14350 of 14745 in total
Mosapramine
Experimental
CAD106
CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease. It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients.
Investigational
4-(2-HYDROXYPHENYLTHIO)-1-BUTENYLPHOSPHONIC ACID
Experimental
(4S)-4-(2-NAPHTHYLMETHYL)-D-GLUTAMIC ACID
Experimental
Ragaglitazar
Investigational
5-(2-NITROPHENYL)-2-FUROIC ACID
Experimental
Alphamethadol
Experimental
Illicit
Displaying drugs 14326 - 14350 of 14745 in total